GlycoMimetics (GLYC)

GlycoMimetics (GLYC) Stock Price & Analysis


GLYC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.51 - $4.16
Previous Close$1.85
Average Volume (3M)396.18K
Market Cap
Enterprise Value$54.50M
Total Cash (Recent Filing)$65.00M
Total Debt (Recent Filing)$651.73K
Price to Earnings (P/E)-2.4
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding64,245,674
10 Day Avg. Volume499,352
30 Day Avg. Volume396,181
Standard Deviation0.34
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue726.72
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.27
Price Target Upside332.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.51 and its highest was $4.16 in the past 12 months.
    What is GlycoMimetics’s market cap?
    Currently, no data Available
    When is GlycoMimetics’s upcoming earnings report date?
    GlycoMimetics’s upcoming earnings report date is Aug 03, 2023 which is in 68 days.
      How were GlycoMimetics’s earnings last quarter?
      GlycoMimetics released its earnings results on May 03, 2023. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.003.
        Is GlycoMimetics overvalued?
        According to Wall Street analysts GlycoMimetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GlycoMimetics pay dividends?
          GlycoMimetics does not currently pay dividends.
          What is GlycoMimetics’s EPS estimate?
          GlycoMimetics’s EPS estimate is -$0.18.
            How many shares outstanding does GlycoMimetics have?
            GlycoMimetics has 64,245,674 shares outstanding.
              What happened to GlycoMimetics’s price movement after its last earnings report?
              GlycoMimetics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went down -3.546%.
                Which hedge fund is a major shareholder of GlycoMimetics?
                Currently, no hedge funds are holding shares in GLYC


                GlycoMimetics Stock Smart Score

                The GlycoMimetics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description


                GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.


                Top 5 ETFs holding GLYC

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold GLYC. The ETFs are listed according to market value of GLYC within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                CytomX Therapeutics
                Alzamend Neuro
                Senti Biosciences
                Olema Pharmaceuticals
                Candel Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis